MediWound Ltd.

NASDAQ:MDWD

Biotechnology

Healthcare
$13.61 -0.60%

-$0.09 today

Market cap
$175.71M
Beta
0.15
P/E (TTM)
-7.0
EPS (TTM)
-$2.03
52W Low $13.54High $21.26

Volume 0.17M

Average 0.09M

MDWD Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

MediWound Ltd.NASDAQ: MDWD

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures growth accelerates

Q1 FY2026 capital expenditures of $1.82M (cash outflow) rose 89.8% year over year, ahead of the +8.2% change in trailing-twelve-month capital expenditures. Sequentially, it fell 26.7% from the prior quarter. Over 3 fiscal years it compounded at +114.9% a year.

Context

  • Capital expenditures amounted to 32.5% of revenue in FY2025, up 1.4 pp from a year earlier.
  • Capital expenditures grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +89.8% holds above the trailing-twelve-month pace of +8.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.82M-26.7% QoQ
Last fiscal yearDec 2025
-$5.51M-12.2% YoY
LTMMar 2026
-$6.46M+8.2% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+89.8%——
1 year-12.2%——
3-year CAGR+114.9%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(5.51M) USD
Year-over-year change
+12.2%

Capital Expenditures vs competitors

How MDWD compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +8.2% is the 4th highest of 8, against a peer median of -8.7%.
  • Capital expenditures amounts to 44.6% of revenue for MDWD, versus a peer median of 3.5%.
MDWD Competitors
Capital Expenditures for MDWD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MDWDMediWound Ltd.LTM Mar 2026$6.46M USD+8.2%+114.9%44.6%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$4.41M USD-53.9%+65.6%248.2%
IVVDInvivyd, Inc.LTM Mar 2026$737K USD+411.8%-55.0%1.3%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$728.23K USD+188.5%+36.5%—
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$561K USD+42.7%-6.1%1.7%
IVAInventiva S.A.FY2025€237.26K EUR-28.8%-24.9%5.3%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$95K USD-8.7%——
TARAProtara Therapeutics, Inc.LTM Mar 2026$50K USD-53.3%-7.8%—
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026$8 USD———
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$0 USD———
Peer median (excluding MDWD) —-8.7%-7.0%3.5%

Competitors are the stored peer set for MDWD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(13.55M)(19.6M)(6.72M)(30.22M)(23.88M)
Depreciation & Amortization1.24M1.27M1.3M1.48M1.71M
Deferred Income Tax(124K)0000
Stock-Based Compensation1.67M1.95M1.94M3.14M3.11M
Change in Working Capital162K(7.24M)2.34M1.27M4.77M
Accounts Receivables929K(7.58M)4.76M(1.02M)4.88M
Inventory257K(721K)(906K)187K(1.36M)
Accounts Payables1.72M414K(594K)406K2.35M
Other Working Capital(2.75M)645K(928K)1.7M(1.1M)
Other Non-Cash Items1.69M11.74M(9.33M)10.71M(236K)
Operating Cash Flow(8.92M)(11.89M)(10.47M)(13.62M)(14.53M)
Capital Expenditures(489K)(555K)(6.46M)(6.27M)(5.51M)
Acquisitions (Net)00000
Purchases of Investments0000(14.04M)
Sales of Investments4M0000
Other Investing Activities35K74K(27.86M)(2.12M)0
Investing Cash Flow3.55M(481K)(34.32M)(8.4M)(19.54M)
Debt Repayment000(928K)0
Common Stock Issued3K38.38M24.91M22.17M31.05M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.05M)(2.62M)(1.99M)(1.84M)(1.43M)
Financing Cash Flow(1.05M)35.76M22.92M19.39M29.62M
Effect of Forex Changes88K(549K)(160K)(84K)95K
Net Change in Cash(6.33M)22.85M(22.03M)(2.71M)(4.36M)
Free Cash Flow(9.41M)(12.44M)(16.93M)(19.9M)(20.04M)

MediWound Ltd.

NASDAQ:MDWD

Intrinsic Alpha fair value

Locked

Current Price

$13.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.